The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition ...
MedPage Today on MSN
First TAVR System Approved for Severe Aortic Regurgitation
Limited launch expected for JenaValve's Trilogy System ...
BACKGROUND: Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification ...
Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, outcomes were similar among patients who had undergone transcatheter aortic-valve ...
Bicuspid aortic valve (BAV) is a common congenital heart defect where the aortic valve has two leaflets (cusps) instead of the usual three, resulting in abnormal blood flow and development of aortic ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Credit: Getty Images Clinicians must be vigilant for subtle signs of BAV in children. Once diagnosed, management decisions should be individualized. Bicuspid aortic valve (BAV) is the most common ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Your heart has four valves, which keep your blood flowing in the right direction. If one doesn’t work correctly, it can put you at higher risk for stroke or congestive heart failure. More than 182,000 ...
Bicuspid aortic valve affects up to one in 50 people, but many don't know they have this congenital heart defect until symptoms appear in middle age ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results